Positive News Sentiment NASDAQ:ABUS Arbutus Biopharma - ABUS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.93 +0.06 (+2.09%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.86▼$2.9650-Day Range$2.22▼$2.9352-Week Range$1.85▼$3.64Volume409,583 shsAverage Volume843,843 shsMarket Capitalization$439.36 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arbutus Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside121.8% Upside$6.50 Price TargetShort InterestHealthy3.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.88Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.46) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector853rd out of 1,048 stocksPharmaceutical Preparations Industry423rd out of 513 stocks 3.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Arbutus Biopharma has a forecasted upside of 121.8% from its current price of $2.93.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.14% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 0.63%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABUS. Previous Next 3.8 News and Social Media Coverage News SentimentArbutus Biopharma has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arbutus Biopharma this week, compared to 1 article on an average week.Search InterestOnly 21 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat Follows4 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by InstitutionsOnly 31.03% of the stock of Arbutus Biopharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.46) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arbutus Biopharma (NASDAQ:ABUS) StockArbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.Read More Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Stock News HeadlinesJanuary 21, 2023 | americanbankingnews.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest UpdateJanuary 5, 2023 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Announces 2023 Corporate Objectives and Provides Financial UpdateJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 5, 2023 | finance.yahoo.comArbutus Announces 2023 Corporate Objectives and Provides Financial UpdateDecember 13, 2022 | finance.yahoo.comArbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus InfectionDecember 12, 2022 | msn.comArbutus Biopharma's Return On Capital Employed InsightsDecember 8, 2022 | finance.yahoo.comCompanies Like Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Invest In GrowthNovember 30, 2022 | bizjournals.comTRADING JABSJanuary 27, 2023 | UNKNOWN (Ad)Become an Investor in Brooklyn GinAward winning super-premium craft gin and upcoming Brooklyn distilleryNovember 11, 2022 | finance.yahoo.comArbutus Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 9, 2022 | seekingalpha.comArbutus trades higher as Q3 net loss narrows, revenue grows on license dealNovember 9, 2022 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 8, 2022 | finance.yahoo.comArbutus to Present at Jefferies London Healthcare ConferenceNovember 2, 2022 | apnews.comArbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®November 1, 2022 | finance.yahoo.comArbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®October 31, 2022 | finance.yahoo.comArbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022October 26, 2022 | finance.yahoo.comArbutus to Report Third Quarter 2022 Financial Results and Provide Corporate UpdateOctober 9, 2022 | finance.yahoo.comInvestors in Arbutus Biopharma (NASDAQ:ABUS) have made a strong return of 105% over the past three yearsOctober 5, 2022 | nasdaq.comWe Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business GrowthSeptember 30, 2022 | finance.yahoo.comGaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year EndSeptember 22, 2022 | finance.yahoo.comArbutus to Present at Chardan’s 6th Annual Genetic Medicines ConferenceSeptember 12, 2022 | seekingalpha.comArbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'September 6, 2022 | finance.yahoo.comArbutus to Participate in September Investor ConferencesSeptember 1, 2022 | finance.yahoo.comBucks County biopharm firm issued key patent in pursuit of hepatitis B cureAugust 30, 2022 | finance.yahoo.comArbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729August 10, 2022 | finance.yahoo.comAnalysts Just Shipped A Dazzling Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) EstimatesAugust 8, 2022 | nasdaq.comBullish: Analysts Just Made A Noticeable Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) ForecastsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Company Calendar Last Earnings11/09/2022Today1/26/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees85Year Founded1992Price Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$9.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+121.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,250,000.00 Net Margins-191.34% Pretax Margin-178.99% Return on Equity-43.44% Return on Assets-31.98% Debt Debt-to-Equity RatioN/A Current Ratio5.13 Quick Ratio5.13 Sales & Book Value Annual Sales$10.99 million Price / Sales39.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book2.50Miscellaneous Outstanding Shares149,951,000Free Float142,154,000Market Cap$439.36 million OptionableOptionable Beta2.13 Social Links Key ExecutivesWilliam H. CollierPresident, Chief Executive Officer & DirectorMichael J. McElhaughChief Operating OfficerDavid C. HastingsChief Financial & Accounting OfficerMichael J. SofiaChief Scientific OfficerElizabeth HowardSecretary, Chief Compliance Officer & EVPKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDANGM BiopharmaceuticalsNASDAQ:NGMEntrada TherapeuticsNASDAQ:TRDALexicon PharmaceuticalsNASDAQ:LXRXEagle PharmaceuticalsNASDAQ:EGRXView All CompetitorsInsiders & InstitutionsClear Harbor Asset Management LLCBought 53,000 shares on 1/20/2023Ownership: 0.035%Assenagon Asset Management S.A.Sold 1,077,587 shares on 1/12/2023Ownership: 0.545%Bank of New York Mellon CorpBought 30,612 shares on 12/8/2022Ownership: 0.257%BNP Paribas Arbitrage SNCBought 14,832 shares on 11/16/2022Ownership: 0.026%Verus Capital Partners LLCBought 27,700 shares on 11/16/2022Ownership: 0.018%View All Institutional Transactions ABUS Stock - Frequently Asked Questions Should I buy or sell Arbutus Biopharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares. View ABUS analyst ratings or view top-rated stocks. What is Arbutus Biopharma's stock price forecast for 2023? 4 brokerages have issued 1 year price targets for Arbutus Biopharma's shares. Their ABUS share price forecasts range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 121.8% from the stock's current price. View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts. How have ABUS shares performed in 2023? Arbutus Biopharma's stock was trading at $2.33 at the start of the year. Since then, ABUS stock has increased by 25.8% and is now trading at $2.93. View the best growth stocks for 2023 here. When is Arbutus Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our ABUS earnings forecast. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) posted its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The biopharmaceutical company had revenue of $5.95 million for the quarter, compared to analyst estimates of $11.12 million. Arbutus Biopharma had a negative net margin of 191.34% and a negative trailing twelve-month return on equity of 43.44%. What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX). What is Arbutus Biopharma's stock symbol? Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS." Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.55%) and Clear Harbor Asset Management LLC (0.04%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arbutus Biopharma's stock price today? One share of ABUS stock can currently be purchased for approximately $2.93. How much money does Arbutus Biopharma make? Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $439.36 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76,250,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. How can I contact Arbutus Biopharma? Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201. This page (NASDAQ:ABUS) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.